Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Thyroid Cancer, Papillary 1Sarcoma, Endometrial Stromal 1Neoplasm Metastasis 1Liver Neoplasms 1Leukemia, Hairy Cell 1Duodenal Neoplasms 1Carcinoma, Lobular 1Carcinoma, Hepatocellular 1Anatomic Stage I Breast Cancer AJCC v8 1Agnosia 1Adrenocortical Adenoma 1Adenocarcinoma, Follicular 1

Interventions

Bevacizumab 23Sorafenib 20Doxorubicin 14Gemcitabine 11durvalumab 10Oxaliplatin 10Fluorouracil 10Cisplatin 10Capecitabine 9Nivolumab 8pembrolizumab 6Sunitinib 6tremelimumab 5atezolizumab 5Radiofrequency Ablation 5Neoadjuvant Therapy 5Leucovorin 5lenvatinib 4aldesleukin 4Thalidomide 4Radiotherapy 4Radiosurgery 4Everolimus 4Erlotinib Hydrochloride 4Drug Therapy 4Carboplatin 4toripalimab 3regorafenib 3camrelizumab 3apatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liver Neoplasms × High-Energy Shock Waves × Clear all
NCT00019604 2017-02-03

Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
44 enrolled 7 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡